Stephan R Bohl

TL;DR: A literature search was performed using PubMed to find recent major publications, which provide biological and clinical research about epigenetic therapy in AML patients, and some of them, such as AZA plus venetoclax, already show promising results.

TL;DR: Seven new targeted agents have received US Food and Drug Administration approval for the treatment of AML and have especially improved AML patient outcomes if they are combined with conventional therapy.

TL;DR: Despite the very good response in the eculizumab-treated group, further studies are needed to identify the optimal therapeutic management approach for transplantation-associated thrombotic microangiopathy to improve its dismal outcome.

TL;DR: Rapid differential diagnosis is needed in order to determine the specifictype of thrombotic microangiopathy that is present, because only patients with TTP and only a very small percentage of those with atypical hemolytic-uremic syndrome (aHUS) can benefit from plasmapheresis.

TL;DR: The identified miR-139-5p as a myeloid-specific miRNA with expression being restricted to neutrophils and macrophages and pointed towards a possible deregulation in malignant hematopoiesis, which reinforces the unfavorable outcome of CN-AML patients with low miR+5p levels.